Acorda Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

ACOR 25.50 +0.10 (0.39%)
price chart
Acorda Therapeutics up 7% on patent ruling
Update: Hedge fund honcho Kyle Bass was the challenger through his Coalition for Affordable Drugs. The USPTO ruled that the information he used to support his petition was not publicly available so it could not be used to invalidate the patents.
Acorda Therapeutics Higher Off Favorable Patent Ruling Related To Ampyra  Benzinga
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Files An 8-K Other Events  Market Exclusive
Why Acorda Therapeutics Stock Is Jumping Today
As of 10:47 a.m. EST Thursday, shares of specialty pharmaceutical company Acorda Therapeutics (NASDAQ:ACOR) were up by more than 15%.
JP Morgan Provides Thoughts On Acorda Therapeutics Inc (ACOR)  Smarter Analyst
Acorda Therapeutics (ACOR) Phase 3 Trial CVT-30 Shows Statistically ...
Acorda Therapeutics Can Deliver Sustained Growth
Acorda Therapeutics (NASDAQ:ACOR) is a small biotech (market cap of $1.20 billion) that markets three products for patients suffering from the effects of multiple sclerosis (MS), spinal cord injury (SCI), stroke, and neuropathic pain (Table 1).
Acorda Up, But Patent Battle Looms
Positive phase III results for Acorda's (NASDAQ:ACOR) inhaled levodopa CVT-301 sent the company's stock up 21% yesterday but, with its multiple sclerosis therapy Ampyra facing two patent decisions this quarter, sales of Acorda's biggest earner could ...
Acorda Therapeutics, Inc. (Nasdaq:ACOR) could bounce on good earnings data ...  FinancialsTrend
Stocks on the Move: Acorda Therapeutics, Inc. (NASDAQ:ACOR), Akamai ...  TRA
Acorda Therapeutics (ACOR) Jumps: Stock Adds 6.5% in Session
Acorda Therapeutics, Inc. ACOR was a big mover last session, as its shares rose above 6% on the day. The move came after the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld all four patents challenged ...
Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that Catherine D. Strader, Ph.D., has joined its board of directors, effective February 17.
Acorda Therapeutics, Inc. (ACOR) Given a $22.00 Price Target at Cantor ...  Chaffey Breeze
Acorda Therapeutics: Punished By A “Small Disappointment”
Dalfampridine had promising results in a phase 2 trial. The latest results, however, failed to show sufficient efficacy, the company announced. Now, Acorda plans to focus on its two late-stage therapies for Parkinson's disease - CVT-301 and tozadenant ...
Acorda Therapeutics plummets as much as 13% on failed trial, discontinued ...  MarketWatch
Stock Update (NASDAQ:ACOR): Here's Why Acorda Therapeutics Inc Shares ...  Smarter Analyst
Numeric Investors LLC Buys New Position in Acorda Therapeutics Inc (ACOR)
Acorda Therapeutics logo Numeric Investors LLC bought a new position in Acorda Therapeutics Inc (NASDAQ:ACOR) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission.
Vetr Inc. Upgrades Acorda Therapeutics Inc (ACOR) to “Strong-Buy”  Chaffey Breeze
The Vetr Inc. Upgrades Acorda Therapeutics Inc (ACOR) to “Strong-Buy”  Petro Global News 24
Acorda Therapeutics Has Significant Upside From Its Current Stock Price
Acorda Therapeutics (NASDAQ: ACOR) is a central nervous system (CNS) focused emerging biopharmaceutical company. The company's pipeline includes products targeted at areas of unmet need like OFF symptoms of Parkinson's disease (PD), ...
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q3 2016 Results - Earnings Call ...
Welcome to the Acorda Therapeutics Third Quarter Update. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow.